The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF▼ Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.
Understand the evidence from the Guidelines
Dosing guidelines and recommended dosing modifications
if you require more detailed information on BOSULIF, please go to Medical Information
watch leading specialists discuss the data from the Explore More section below
go to the Patient Support page to access support items for patients
Watch Prof. Richard Clark discuss the holistic approach to treatment decisions for patient with CML
Watch the video
Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video
For Great Britain
Bosulif (bosutinib) Prescribing Information - 100mg Tablets
Bosulif (bosutinib) Prescribing Information - 400mg Tablets
Bosulif (bosutinib) Prescribing Information - 500mg Tablets
For Northern Ireland
Bosulif (bosutinib) Prescribing Information
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020